JSKN033

Phase 3Small molecule

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

JSKN033 is one of 64 small molecule programs targeting Recurrent or Metastatic Cervical Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent or Metastatic Cervical CancerNot yet recruiting

Advanced Malignant TumorsNot yet recruiting

Non-Small Cell Lung CancerNot yet recruiting

Recurrent or Metastatic Cervical CancerPhase 3

Not yet recruiting

Advanced Malignant TumorsPhase 2

Not yet recruiting

Non-Small Cell Lung CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

Anktiva

SSWOG Cancer Research Network

Phase 3

1 3

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 4

JSKN033

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT07283198

Q4 2027

Phase 1/2Not yet recruiting

Advanced Malignant Tumors

NCT06770881

Q4 2029

Phase 3Not yet recruiting

Recurrent or Metastatic Cervical Cancer

NCT07797153

Clinical

Trials by Indication[1]

Malignant Tumors1 trial

JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

Terminated·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT06226766·11 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT07283198·160 enrolled

Advanced Malignant Tumors1 trial

JSKN033 in Chinese Subjects with Advanced Malignant Tumors

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT06770881·430 enrolled

Recurrent or Metastatic Cervical Cancer1 trial

A Randomized, Controlled, Open-Label, Multi-center, Phase III Study of JSKN033 Versus Investigator's Choice of Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Platinum-Based Chemotherapy and PD-1/L1 Inhibitor Therapy

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 3·NCT07797153·368 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for JSKN033. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JSKN033 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JSKN033. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Alphamab Biopharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu Alphamab Biopharmaceuticals Co., Ltd

JSKN033

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q4 2029

Trials by Indication[1]

Malignant Tumors1 trial

Non-Small Cell Lung Cancer1 trial

Advanced Malignant Tumors1 trial

Recurrent or Metastatic Cervical Cancer1 trial

References

Drug Info

Quick Facts

Related News